Ergomed Plc (LON:ERGO) has been reiterated to Buy in a statement by N+1 Singer earlier today.
- Updated: September 25, 2016
Having a price of 121.50GBX, Ergomed Plc (LON:ERGO) traded 0.83% higher on the day. With the last close down -11.35% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Ergomed Plc has recorded a 50-day average of 119.97GBX and a two hundred day average of 136.49GBX. Volume of trade was up over the average, with 16,015 shares of ERGO changing hands over the typical 6,113
N+1 Singer has reiterated Ergomed Plc (LON:ERGO) to Buy in a statement released on Monday September 26, 2016.
On 09/22/2016, Stifel released a statement on Ergomed Plc (LON:ERGO) maintained the target price at 271.00GBX that suggested an upside of 1.25%.
With a total market value of 0 GBX, Ergomed Plc has price-earnings ratio of 23.27 with a one year low of 117.00GBX and a one year high of 173.74GBX .
More About Ergomed Plc (LON:ERGO)
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.